{"gao_id": "GAO-19-83", "published": "2018-11-30T12:00:00Z", "released": "2018-11-30T07:00:00Z", "summary": "How do you get drug manufacturers to make drugs that treat rare diseases\u2014when they may not sell enough to make a profit? The Food and Drug Administration designates some drugs as \"orphan drugs,\" which allows manufacturers to obtain incentives (like tax breaks) for developing drugs that treat rare diseases. But we found that FDA reviewers don\u2019t always include all the required information in their reviews...", "title": "Orphan Drugs: FDA Could Improve Designation Review Consistency; Rare Disease Drug Development Challenges Continue", "topics": ["Prescription drugs", "Timeliness", "New drugs", "Patient care", "Health Care", "Pediatrics", "Diseases", "Drug approvals", "Orphan drugs", "Tax credit", "Drugs", "Marketing"], "type": "reports-testimonies", "url": "https://www.gao.gov/products/gao-19-83", "versions": [{"title": "Highlights Page (1 page)", "url": "https://www.gao.gov/assets/gao-19-83-highlights.pdf"}, {"title": "Full Report (50 pages)", "url": "https://www.gao.gov/assets/gao-19-83.pdf"}, {"title": "Accessible PDF (59 pages)", "url": "https://www.gao.gov/assets/700/695823.pdf"}]}